English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Vashchenko L.N., Karnaukhov N.S., Gudtskova T.N., Kvarchiya M.V. Aims. The research was aimed at a comparative study of the expression levels of Ki-67 and cyclin D1 in subtypes of triple-negative breast cancer (TNBC) with varying androgenic status. Materials and methods. Surgical material was studied from 60 patients of clinical group 2A, clinical stage T1-2N0M0, treated at Rostov Research Institute of Oncology, from 2012 to 2015. In all cases, the surgery was the first stage of treatment. Antibodies to estrogen, progesterone, and androgen receptors, cytokeratin 5/6, Ki-67, cyclin D1, and proteins HER2/neu and EGFR were used for the immune histochemical test. Results. It was found that a significantly higher level of Ki-67 expression was observed in TNBC with signs of basal epithelium in comparison with other TNBC, however, the level of cyclin D1 expression was inconclusive. Overexpression of cyclin D1 was observed in the part of TNBC that had no correlation with the Ki-67 expression level. High levels of cyclin D1 in the basal-like TNBC was less frequent than in TNBC without signs of basal epithelium, but its mean value was significantly higher. The level of Ki-67 did not differ significantly in TNBC with different androgenic status. Overexpression of cyclin D1 was more common among androgen-positive TNBC, and its mean value was significantly higher compared to the androgen-negative tumor. Conclusions. Ki-67 proliferation marker and cyclin D1 cell cycle regulator can be used as additional criteria for monitoring the course of TNBC subtypes.

COMPARISON OF THE LEVEL OF EXPRESSION OF PROLIFERATION MARKERS KI-67 AND CYCLIN D1 IN TRIPLE-NEGATIVE BREAST CANCER WITH DIFFERENT ANDROGENIC STATUS